
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” regarding a future IPO, its CEO said.

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” regarding a future IPO, its CEO said.